{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T15:45:46Z","timestamp":1788363946081,"version":"build-2803163510"},"reference-count":44,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,8,15]],"date-time":"2021-08-15T00:00:00Z","timestamp":1628985600000},"content-version":"vor","delay-in-days":14,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2021,8]]},"DOI":"10.1016\/j.critrevonc.2021.103418","type":"journal-article","created":{"date-parts":[[2021,7,9]],"date-time":"2021-07-09T00:32:14Z","timestamp":1625790734000},"page":"103418","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"C","title":["The clinical applicability of current prognostic models in follicular lymphoma: A systematic review"],"prefix":"10.1016","volume":"164","author":[{"given":"Jelena","family":"Jelicic","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Stauffer Larsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zoran","family":"Bukumiric","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bosko","family":"Andjelic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.critrevonc.2021.103418_bib0005","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1182\/bloodadvances.2019032136","article-title":"Impact of age on clinical risk scores in follicular lymphoma","volume":"3","author":"Alig","year":"2019","journal-title":"Blood Adv."},{"key":"10.1016\/j.critrevonc.2021.103418_bib0010","first-page":"26","article-title":"Bolesnici sa folikularnim limfomom, visokim FLIPI skorom i velikom tumorskom masom: model za odre\u0111ivanje rizika","volume":"72","author":"Andjeli\u0107","year":"2015","journal-title":"Vojnosanit. Pregl."},{"key":"10.1016\/j.critrevonc.2021.103418_bib0015","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.leukres.2005.07.006","article-title":"Correlation of the FLIPI score for follicular lymphoma with period of diagnosis and type of treatment","volume":"30","author":"Arcaini","year":"2006","journal-title":"Leuk. Res."},{"key":"10.1016\/j.critrevonc.2021.103418_bib0020","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1111\/j.1365-2141.2009.08065.x","article-title":"Validation of follicular lymphoma international prognostic index 2 (FLIPI2) score in an independent series of follicular lymphoma patients","volume":"149","author":"Arcaini","year":"2010","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.critrevonc.2021.103418_bib0025","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1182\/blood-2017-11-816405","article-title":"A simplified scoring system in de novo follicular lymphoma treated initially with immunochemotherapy","volume":"132","author":"Bachy","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2021.103418_bib0030","doi-asserted-by":"crossref","first-page":"e80","DOI":"10.1016\/S2352-3026(20)30365-3","article-title":"The role of PET in the first-line treatment of the most common subtypes of non-Hodgkin lymphoma","volume":"8","author":"Barrington","year":"2021","journal-title":"Lancet Haematol."},{"key":"10.1016\/j.critrevonc.2021.103418_bib0035","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2018-99-117235","article-title":"Baseline PET-derived metabolic tumor volume metrics did not predict outcomes in follicular lymphoma patients treated with first-line immunochemotherapy and antibody maintenance in the phase III GALLIUM study","volume":"132","author":"Barrington","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2021.103418_bib0040","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1002\/hon.7_2630","article-title":"Treatment-dependence of high-risk gene expression signatures in de NOVO follicular lymphoma","volume":"37","author":"Bolen","year":"2019","journal-title":"Hematol. Oncol."},{"key":"10.1016\/j.critrevonc.2021.103418_bib0045","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1182\/blood-2006-01-013367","volume":"108","author":"Buske","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2021.103418_bib0050","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1200\/JCO.2014.59.7534","article-title":"Early relapse of follicular lymphoma after rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone defines patients at high risk for death: an analysis from the National LymphoCare Study","volume":"33","author":"Casulo","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2021.103418_bib0055","doi-asserted-by":"crossref","first-page":"2094","DOI":"10.1093\/annonc\/mdx189","article-title":"Unmet needs in the first-line treatment of follicular lymphoma","volume":"28","author":"Casulo","year":"2017","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2021.103418_bib0060","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","article-title":"A new method of classifying prognostic comorbidity in longitudinal studies: development and validation","volume":"40","author":"Charlson","year":"1987","journal-title":"J. Chronic Dis."},{"key":"10.1016\/j.critrevonc.2021.103418_bib0065","doi-asserted-by":"crossref","first-page":"2449","DOI":"10.1182\/blood-2017-11-816298","article-title":"Prognostic model for high-tumor-burden follicular lymphoma integrating baseline and end-induction PET: a LYSA\/FIL study","volume":"131","author":"Cottereau","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2021.103418_bib0070","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1056\/NEJMoa041869","article-title":"Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells","volume":"351","author":"Dave","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2021.103418_bib0075","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.3324\/haematol.11502","article-title":"Prognostic relevance of serum \u03b22 microglobulin in patients with follicular lymphoma treated with anthracycline-containing regimens. A GISL study","volume":"92","author":"Federico","year":"2007","journal-title":"Haematologica"},{"key":"10.1016\/j.critrevonc.2021.103418_bib0080","doi-asserted-by":"crossref","first-page":"4555","DOI":"10.1200\/JCO.2008.21.3991","article-title":"Follicular lymphoma international prognostic index 2: a new prognostic index for follicular lymphoma developed by the international follicular lymphoma prognostic factor project","volume":"27","author":"Federico","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2021.103418_bib0085","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1159\/000253026","article-title":"Utility of the follicular lymphoma international prognostic index and the international prognostic index in assessing prognosis and predicting first-line treatment efficacy in follicular lymphoma patients","volume":"122","author":"Formica","year":"2009","journal-title":"Acta Haematol."},{"key":"10.1016\/j.critrevonc.2021.103418_bib0090","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1002\/ajh.25696","article-title":"Follicular lymphoma: 2020 update on diagnosis and management","volume":"95","author":"Freedman","year":"2020","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.critrevonc.2021.103418_bib0095","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1097\/PRS.0b013e318200afa9","article-title":"Systematic reviews and meta-analysis","volume":"127","author":"Haase","year":"2011","journal-title":"Plast. Reconstr. Surg."},{"key":"10.1016\/j.critrevonc.2021.103418_bib0100","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1111\/j.1365-2141.2005.05508.x","article-title":"A population-based study of severity of comorbidity among patients with non-Hodgkin\u2019s lymphoma: prognostic impact independent of International Prognostic Index","volume":"129","author":"Janssen-Heijnen","year":"2005","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.critrevonc.2021.103418_bib0105","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1182\/blood-2016-05-717355","article-title":"Clinicogenetic risk models predict early progression of follicular lymphoma after first-line immunochemotherapy","volume":"128","author":"Jurinovic","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2021.103418_bib0110","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1182\/asheducation-2017.1.358","article-title":"Follicular lymphoma: are we ready for a risk-adapted approach?","volume":"2017","author":"Kahl","year":"2017","journal-title":"Hematology"},{"key":"10.1016\/j.critrevonc.2021.103418_bib0115","doi-asserted-by":"crossref","DOI":"10.1111\/bjh.16692","article-title":"The simplified follicular lymphoma PRIMA-prognostic index is useful in patients with first-line chemo-free rituximab-based therapy","author":"Kimby","year":"2020","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.critrevonc.2021.103418_bib0120","doi-asserted-by":"crossref","first-page":"4632","DOI":"10.1158\/1078-0432.CCR-18-3270","article-title":"Prognostic impact of natural killer cell count in follicular lymphoma and diffuse large b-cell lymphoma patients treated with immunochemotherapy","volume":"25","author":"Klanova","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.critrevonc.2021.103418_bib0125","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.1007\/s11999-010-1538-7","article-title":"Statistics in brief: How to assess bias in clinical studies?","volume":"469","author":"Lambert","year":"2011","journal-title":"Clin. Orthop. Relat. Res."},{"key":"10.1016\/j.critrevonc.2021.103418_bib0130","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1111\/bjh.16159","article-title":"M7-FLIPI is not prognostic in follicular lymphoma patients with first-line rituximab chemo-free therapy","volume":"188","author":"Lockmer","year":"2020","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.critrevonc.2021.103418_bib0135","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1182\/blood-2004-08-3175","article-title":"CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma","volume":"105","author":"Marcus","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2021.103418_bib0140","doi-asserted-by":"crossref","first-page":"3618","DOI":"10.1200\/JCO.2016.66.9440","article-title":"Baseline metabolic tumor volume predicts outcome in high-tumor-burden follicular lymphoma: a pooled analysis of three multicenter studies","volume":"34","author":"Meignan","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2021.103418_bib0145","doi-asserted-by":"crossref","DOI":"10.1007\/s12185-016-2099-7","article-title":"FCG (FLIPI, Charlson comorbidity index, and histological grade) score is superior to FLIPI in advanced follicular lymphoma","volume":"104","author":"Mihaljevic","year":"2016","journal-title":"Int. J. Hematol."},{"key":"10.1016\/j.critrevonc.2021.103418_bib0150","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1002\/ajh.25973","article-title":"Follicular Lymphoma Evaluation Index (FLEX): a new clinical prognostic model that is superior to existing risk scores for predicting progression\u2010free survival and early treatment failure after frontline immunochemotherapy","volume":"95","author":"Mir","year":"2020","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.critrevonc.2021.103418_bib0155","doi-asserted-by":"crossref","first-page":"1812","DOI":"10.1182\/bloodadvances.2020001579","article-title":"Baseline FDG-PET\/CT detects bone marrow involvement in follicular lymphoma and provides relevant prognostic information","volume":"4","author":"Nakajima","year":"2020","journal-title":"Blood Adv."},{"key":"10.1016\/j.critrevonc.2021.103418_bib0160","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1093\/annonc\/mds429","article-title":"Examination of the follicular lymphoma international prognostic index (FLIPI) in the national lymphocare study (NLCS): a prospective US patient cohort treated predominantly in community practices","volume":"24","author":"Nooka","year":"2013","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2021.103418_bib0165","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1016\/S1470-2045(15)00169-2","article-title":"Integration of gene mutations in risk prognostication for patients receiving first-line immunochemotherapy for follicular lymphoma: a retrospective analysis of a prospective clinical trial and validation in a population-based registry","volume":"16","author":"Pastore","year":"2015","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.critrevonc.2021.103418_bib0170","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1093\/annonc\/mdi269","article-title":"Prognostic indexes in follicular lymphoma: a comparison of different prognostic systems","volume":"16","author":"Perea","year":"2005","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2021.103418_bib0175","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1111\/j.1600-0609.2005.00564.x","article-title":"Follicular lymphoma in early stages: high risk of relapse and usefulness of the Follicular Lymphoma International Prognostic Index to predict the outcome of patients","volume":"76","author":"Plancarte","year":"2006","journal-title":"Eur. J. Haematol."},{"key":"10.1016\/j.critrevonc.2021.103418_bib0180","doi-asserted-by":"crossref","first-page":"6624","DOI":"10.1158\/1078-0432.CCR-13-1120","article-title":"A comparative analysis of prognostic factor models for follicular lymphoma based on a phase III trial of CHOP-rituximab versus CHOP + 131iodine- tositumomab","volume":"19","author":"Press","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.critrevonc.2021.103418_bib0185","article-title":"Baseline SUVmax is related to tumor cell proliferation and patient outcome in follicular lymphoma","author":"Rossi","year":"2021","journal-title":"Haematologica"},{"key":"10.1016\/j.critrevonc.2021.103418_bib0190","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.3324\/haematol.2018.209015","article-title":"Association of early disease progression and very poor survival in the GALLIUM study in follicular lymphoma: Benefit of obinutuzumab in reducing the rate of early progression","volume":"104","author":"Seymour","year":"2019","journal-title":"Haematologica"},{"key":"10.1016\/j.critrevonc.2021.103418_bib0195","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1182\/blood-2003-12-4434","article-title":"Follicular lymphoma international prognostic index","volume":"104","author":"Solal-Celigny","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2021.103418_bib0200","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1007\/s11864-006-0036-3","article-title":"Follicular lymphoma international prognostic index","volume":"7","author":"Solal-Celigny","year":"2006","journal-title":"Curr. Treat. Options Oncol."},{"key":"10.1016\/j.critrevonc.2021.103418_bib0205","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1016\/S1470-2045(18)30618-1","article-title":"Prognostic value of end-of-induction PET response after first-line immunochemotherapy for follicular lymphoma (GALLIUM): secondary analysis of a randomised, phase 3 trial","volume":"19","author":"Trotman","year":"2018","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.critrevonc.2021.103418_bib0210","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1093\/annonc\/mdp053","article-title":"Validation, revision and extension of the Follicular Lymphoma International Prognostic Index (FLIPI) in a population-based setting","volume":"20","author":"van de Schans","year":"2009","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2021.103418_bib0215","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1007\/s002770050521","article-title":"Prevalence of co-morbidity and its relationship to treatment among unselected patients with Hodgkin\u2019s disease and non-Hodgkin\u2019s lymphoma, 1993-1996","volume":"78","author":"van Spronsen","year":"1999","journal-title":"Ann. Hematol."},{"key":"10.1016\/j.critrevonc.2021.103418_bib0220","article-title":"Enhancement of the Follicular Lymphoma International Prognostic Index (FLIPI) with lymphopenia (FLIPI-L): a predictor for overall survival and histologic transformation","volume":"9","author":"Yang","year":"2019","journal-title":"Blood Cancer J."}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842821002067?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842821002067?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T19:40:28Z","timestamp":1760902828000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842821002067"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8]]},"references-count":44,"alternative-id":["S1040842821002067"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2021.103418","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2021,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The clinical applicability of current prognostic models in follicular lymphoma: A systematic review","name":"articletitle","label":"Article Title"},{"value":"Critical Reviews in Oncology\/Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.critrevonc.2021.103418","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"103418"}}